Eli Lilly and Company, Santec Holdings Corporation participated in the round

礼来公司和桑特克控股公司参加了这轮谈判

TOKYO, Jan. 24, 2024 /PRNewswire/ -- TOKYO, Jan. 24, 2024 /PRNewswire/ -- PRISM BioLab, Co. Ltd. ('PRISM'), a leading discovery and development biotechnology company designing small molecule inhibitors of protein-protein interaction (PPI) targets, today announced a 1.5 billion yen ($10.3M) fundraise.

东京，2024年1月24日/PRNewswire/--东京，2024年1月24日/PRNewswire/--PRISM BioLab，Co.Ltd.（“PRISM”），一家领先的发现和开发生物技术公司，设计蛋白质-蛋白质相互作用（PPI）目标的小分子抑制剂，今天宣布筹集15亿日元（1030万美元）的资金。

Funds will be used to refine PRISM's proprietary PepMetics® chemistry platform, expand biology and screening capabilities and advance internal pipeline of PPI inhibitors..

资金将用于改进PRISM专有的PepMetics®化学平台，扩大生物学和筛选能力，并推进PPI抑制剂的内部管道。。

As the numbers of so called 'druggable' targets are dwindling, pharma is gradually turning to PPI targets. Due to frequent involvement in the disease and a sheer number of PPIs, they have long been recognized as a new frontier for drug discovery but the progress has been hampered by the lack of chemistries that can successfully address PPI targets.

随着所谓的“可药用”目标数量的减少，制药公司正逐渐转向PPI目标。由于频繁参与该疾病和大量PPI，它们长期以来被认为是药物发现的新前沿，但由于缺乏能够成功解决PPI目标的化学物质，进展受到阻碍。

PRISM BioLab has early recognized the importance of PPIs as drug targets and has spent over a decade developing proprietary PepMetics® chemical scaffolds that mimic three-dimensional structure of the alpha-helix and beta-turn, peptide structures commonly found in PPI interphases. Today, PepMetics® chemistry enables systematic and reproducible discovery and development of drugs targeting PPIs..

PRISM BioLab很早就认识到PPI作为药物靶标的重要性，并花费了十多年的时间开发了专有的PepMetics®化学支架，该支架模拟了α-螺旋和β-转角的三维结构，这是PPI相间常见的肽结构。今天，PepMetics®化学能够系统且可重复地发现和开发针对PPI的药物。。

'We are confident that our PepMetics® chemistry will become one of the key technologies for the PPI target field,' said Dai Takehara, CEO of PRISM BioLab. 'The funds from this financing round will be used to integrate our PepMetics® chemistry, biology and screening capabilities, to advance our internal pipeline, and to provide greater value to our existing and future pharma partners.

PRISM BioLab首席执行官Dai Takehara说：“我们有信心，我们的PepMetics®化学将成为PPI目标领域的关键技术之一。”这轮融资的资金将用于整合我们的PepMetics®化学、生物学和筛选能力，推进我们的内部渠道，并为我们现有和未来的制药合作伙伴提供更大的价值。

We recognize the importance of partnerships for the success of new approaches to drug discovery and are fortunate to build a long-term relationship with Lilly, a top pharma company, as we move the field forward.'.

我们认识到合作伙伴关系对于药物发现新方法成功的重要性，并且有幸在我们推进该领域的同时，与顶级制药公司礼来建立了长期关系。”。

Comments from investors

投资者意见

Santec Holdings Corporation Executive Vice President & CTO Changho Chong Ph.D.

Santec Holdings Corporation执行副总裁兼首席技术官Changho Chong博士。

We feel confident that PRISM BioLab's promising and unique approach to drug discovery will lead to breakthrough therapeutic drugs that were previously unattainable. Santec is engaged in the development of medical imaging devices and early diagnosis utilizing Photonics. We believe that the advancement of these technologies, in conjunction with innovative drug discovery techniques, is pivotal for the comprehensive improvement of patients' Quality of Life (QoL)..

我们相信，PRISM BioLab有前途且独特的药物发现方法将带来以前无法实现的突破性治疗药物。Santec致力于利用光子学开发医学成像设备和早期诊断。我们相信，这些技术的进步，以及创新的药物发现技术，对于全面改善患者的生活质量（QoL）至关重要。。

About PRISM BioLab

关于PRISM BioLab

PRISM BioLab is a discovery and development biotechnology company utilizing proprietary PepMetics® technology to discover orally available small molecule inhibitors of protein-protein interaction (PPI) targets and transform lives of patients suffering from cancer, autoimmune, fibrosis and other diseases.

PRISM BioLab是一家发现和开发生物技术公司，利用专有的PepMetics®技术发现口服可用的蛋白质-蛋白质相互作用（PPI）靶点小分子抑制剂，并改变患有癌症，自身免疫，纤维化和其他疾病的患者的生活。

PepMetics® are a unique class of small molecules that mimic three-dimensional structures of alpha-helix and beta-turn, the peptide structures commonly found in intracellular PPI interphases and receptor-ligand interactions. By combining proprietary chemistry, know-how around PPI targets and AI-supported design, PepMetics® technology can deliver inhibitors of challenging PPI targets.

PepMetics®是一类独特的小分子，可模拟α-螺旋和β-转角的三维结构，这是细胞内PPI相间和受体-配体相互作用中常见的肽结构。通过结合专有化学、围绕PPI目标的专有技术和AI支持的设计，PepMetics®技术可以提供具有挑战性的PPI目标抑制剂。

The technology holds promise to expand the field of drug discovery by turning previously undruggable PPIs into targets readily druggable with small molecules and by generating oral small molecule alternatives for injectable biologics..

该技术有望通过将以前不可治疗的PPI转化为易于用小分子药物治疗的靶标，并通过产生可注射生物制剂的口服小分子替代品来扩大药物发现领域。。

PRISM BioLab is collaborating on new PPI targets with global and Japanese pharmaceutical companies. PepMetics® targeting CBP/beta-catenin PPIs licensed to Eisai Co., Ltd.  and Ohara Pharmaceuticals Co., Ltd. are in clinical development for cancer and liver disease, respectively.

PRISM BioLab正在与全球和日本制药公司合作制定新的PPI目标。获得卫材株式会社和大原制药株式会社许可的针对CBP/β-连环蛋白的PepMetics®PPI正在分别针对癌症和肝病进行临床开发。

www.prismbiolab.com

www.prismbiolab.com

SOURCE PRISM BioLab Co., Ltd.

SOURCE PRISM生物实验室有限公司。